Janux Therapeutics

Quarterly Financials

Values in thousands 2024-06-30 2024-03-31 2023-12-31 2023-09-30
Revenue
$8,897
$1,252
$2,461
$2,517
Gross Profit
8,391
720
1,930
2,017
EBITDA
-13,316
-19,629
-15,606
-15,813
EBIT
-13,822
-20,161
-16,137
-16,313
Net Income
-5,959
-14,760
-11,758
-11,568
Net Change In Cash
8,897
1,252
2,461
2,517
Free Cash Flow
-10,116
-15,034
-10,416
-12,179
Cash
14,662
212,803
19,205
17,152
Basic Shares
54,451
49,049
46,683
45,708

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$8,083
$8,612
$3,637
$380
Gross Profit
6,128
8,612
3,637
-13
EBITDA
-71,024
-66,250
-32,816
-6,565
EBIT
-72,979
-67,091
-32,929
-6,578
Net Income
-58,293
-54,154
-32,559
-5,255
Net Change In Cash
8,083
8,612
3,637
380
Cost of Revenue
15,844
28,585
Free Cash Flow
-52,425
-49,367
-18,458
-4,369
Cash
19,205
51,426
35,582
7,813
Basic Shares
44,016
41,469
41,243
41,611

Earnings Calls

Quarter EPS
2024-06-30
-$0.11
2024-03-31
-$0.30
2023-12-31
-$0.25
2023-09-30
-$0.25